GrayMatters Health (GMH), an Israel-based company that develops digital self-neuromodulation therapies for mental health care, announced on Wednesday that it has named Kirk Thelander as its new chief commercial officer.
In the new role, Thelander will be responsible for developing and implementing commercial strategies aimed at expediting growth.
Thelander has over 17 years of experience in medical device sales and management, launching mental health technologies and bringing digital therapeutics to new markets. He has previously served in leadership roles at AloeMD, LLC, Greenbrook TMS NeuroHealth Centers, Freespira and Neuronetics, Inc.
SHL Telemedicine introduces SmartHeart direct-to-consumer membership plan
Broncus Hangzhou signs Equity Transfer Agreement with Hangzhou Jingliang shareholders
Bracco signs long-term partnership with ulrich GmbH
L&T Technology Services plans to revolutionise medical imaging in collaboration with NVIDIA
Eli Lilly to build new high-tech manufacturing site in Germany
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Zymo Research's SafeCollect Saliva Collection Kit receives US FDA approval
Kanabo Group extends contract with major UK retailer
Biodesix enhances Nodify Lung testing with Tasso+ blood draw method
Byotrol unveils PROCESSUS instrument decontamination system
Integrum plans FDA PMA submission for OPRA in transhumeral amputations
Telix and Mauna Kea Technologies expand collaboration in urologic oncology surgery
Egetis secures exclusive licence agreement with Fujimoto for Emcitate development in Japan
KDx Diagnostics enters into strategic collaborations with leading distributors in Europe